Syncona investment sells cancer study assets to AstraZeneca for $12m

(Sharecast News) - Life science investor Syncona said its investment Achilles Therapeutics has sold cancer study assets to AstraZeneca for $12m (£9.58m). The deal involves transferring of the commercial license of data and samples from Achilles' TRACERx non-small cell lung cancer study to AstraZeneca, including samples and data.

Achilles added that it intended to cut an unspecified number of jobs and reduce the size of its board of directors.

Completion of this transaction signals the conclusion of the strategic review which was announced in September 2024.

Reporting by Frank Prenesti for Sharecast.com